CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 14, 2020
Result type: Reports
Project Number: SR0655-000
Product Line: Common Drug Review

Generic Name: ranolazine

Brand Name: TBC

Manufacturer: KYE Pharmaceuticals Inc.

Indications: Stable angina pectoris, adults

Manufacturer Requested Reimbursement Criteria1: Indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists). Ranolazine may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJuly 17, 2020
Call for patient input closedSeptember 08, 2020

- No patient input submission received

Submission receivedAugust 17, 2020
Submission acceptedAugust 31, 2020
Review initiatedSeptember 01, 2020

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for commentNovember 16, 2020
Deadline for sponsors commentsNovember 25, 2020
CADTH responses on draft review report(s) provided to sponsorJanuary 08, 2021
Expert committee meeting (initial)January 20, 2021
Draft recommendation issuedFebruary 01, 2021
February 03, 2021